In short
NECVAX-NEO1 is an innovative drug currently being studied in clinical trials for its potential in treating various types of cancer. These trials aim to assess the safety, tolerability, and effectiveness of NECVAX-NEO1 when used in combination with other cancer treatments, particularly immunotherapy drugs known as PD-1 or PD-L1 inhibitors. The studies focus on patients with advanced solid tumors and triple-negative breast cancer, offering hope for new treatment options in challenging cancer cases.
At a glance
- Drug Name
- NECVAX-NEO1
- Trial Types
- Phase I/II, open-label, multicenter
- Cancer Types
- Advanced solid tumors, Triple-negative breast cancer (TNBC)
- Combination Therapy
- Used with PD-1 or PD-L1 inhibitors
- Primary Objectives
- Assess safety and tolerability
- Secondary Objectives
- Evaluate antitumor activity, clinical efficacy, overall survival
- Key Measurements
- Adverse events, laboratory parameters, ctDNA levels, tumor response (RECIST 1.1, iRECIST)
- Eligibility
- Adult patients with specific cancer types, adequate organ function, ability to follow trial instructions
- Administration
- Oral liquid or infusion
What is NECVAX-NEO1?
NECVAX-NEO1 is a novel investigational drug being developed by NEC Bio Therapeutics GmbH for the treatment of advanced solid tumors and triple-negative breast cancer (TNBC). It is currently undergoing clinical trials to assess its safety, tolerability, and effectiveness when used in combination with other cancer treatments.
How does NECVAX-NEO1 work?
NECVAX-NEO1 is designed to work in conjunction with immunotherapy drugs known as PD-1 or PD-L1 inhibitors. These inhibitors help the immune system recognize and attack cancer cells. NECVAX-NEO1 is believed to enhance the effectiveness of these immunotherapies, potentially leading to better outcomes for patients.
What conditions does NECVAX-NEO1 treat?
NECVAX-NEO1 is being investigated for the treatment of: Advanced solid tumors: These are cancers that form solid masses in various parts of the body and have progressed to an advanced stage. Triple-negative breast cancer (TNBC): This is an aggressive type of breast cancer that lacks three common receptors found in other breast cancers, making it more challenging to treat.
Current Clinical Trials
Two clinical trials are currently underway to evaluate NECVAX-NEO1: NECVAX-NEO1-02-INT: This is an open-label, Phase I/II multicenter trial studying NECVAX-NEO1 in combination with PD-1 or PD-L1 inhibitors for patients with advanced solid tumors. NECVAX-NEO1-05-DE: This is an open-label, Phase I/II multicenter trial investigating NECVAX-NEO1 as an add-on to first-line neoadjuvant anti-PD-1 therapy in patients with triple-negative breast cancer. These trials aim to assess the safety, tolerability, and effectiveness of NECVAX-NEO1 when used alongside other cancer treatments.
How is NECVAX-NEO1 administered?
NECVAX-NEO1 is administered as an oral liquid. In some cases, it may also be given through infusion. The exact dosage and administration schedule will depend on the specific clinical trial and the patient's individual needs.
Who is eligible for NECVAX-NEO1 treatment?
Eligibility criteria for NECVAX-NEO1 treatment in clinical trials typically include: Adults aged 18 years or older Diagnosis of advanced solid tumors or triple-negative breast cancer Adequate organ function (kidney, liver, bone marrow) ECOG performance status of 2 or less (a measure of a patient's ability to perform daily activities) Life expectancy of at least 6-12 months Patients with certain medical conditions, such as active infections, autoimmune diseases, or a history of organ transplantation, may not be eligible for these trials.
Potential Side Effects
As NECVAX-NEO1 is still in clinical trials, the full range of potential side effects is not yet known. The ongoing studies are closely monitoring for adverse events and changes in laboratory parameters, physical examinations, vital signs, and electrocardiograms. Patients participating in these trials will be closely monitored for any potential side effects.
Future Research and Potential
The ongoing clinical trials for NECVAX-NEO1 are exploring several important aspects of its potential as a cancer treatment: Its ability to enhance the effectiveness of immunotherapy drugs Its impact on circulating tumor DNA (ctDNA), which can be an indicator of treatment response Its effects on overall survival and progression-free survival in cancer patients Its potential to improve outcomes in difficult-to-treat cancers like triple-negative breast cancer The results of these trials will help determine the future of NECVAX-NEO1 as a potential new treatment option for cancer patients.